Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIIB logo BIIB
Upturn stock ratingUpturn stock rating
BIIB logo

Biogen Inc (BIIB)

Upturn stock ratingUpturn stock rating
$137.33
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: BIIB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -20.5%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 20.27B USD
Price to earnings Ratio 12.37
1Y Target Price 201.52
Price to earnings Ratio 12.37
1Y Target Price 201.52
Volume (30-day avg) 1416996
Beta -0.08
52 Weeks Range 128.51 - 238.00
Updated Date 02/15/2025
52 Weeks Range 128.51 - 238.00
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 11.1

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-11
When Before Market
Estimate 3.3639
Actual 3.44

Profitability

Profit Margin 16.87%
Operating Margin (TTM) 20.47%

Management Effectiveness

Return on Assets (TTM) 5.34%
Return on Equity (TTM) 10.36%

Valuation

Trailing PE 12.37
Forward PE 8.36
Enterprise Value 24520910027
Price to Sales(TTM) 2.09
Enterprise Value 24520910027
Price to Sales(TTM) 2.09
Enterprise Value to Revenue 2.53
Enterprise Value to EBITDA 8.67
Shares Outstanding 146375008
Shares Floating 145325551
Shares Outstanding 146375008
Shares Floating 145325551
Percent Insiders 0.3
Percent Institutions 93.13

AI Summary

Biogen Inc. Stock Analysis

Company Profile:

History and Background:

Founded in 1978, Biogen Inc. is a global biotechnology company headquartered in Cambridge, Massachusetts. It is a pioneer in the development and commercialization of innovative therapies for neurological and neurodegenerative diseases.

Core Business Areas:

Biogen focuses on four key therapeutic areas:

  • Multiple Sclerosis (MS): Biogen is a leader in the MS market, offering a range of disease-modifying therapies.
  • Neuroscience: Biogen develops treatments for Alzheimer's disease, Parkinson's disease, and other neurological disorders.
  • Hematology: Biogen offers treatments for hemophilia and other blood disorders.
  • Immunology: Biogen's research and development efforts are focused on developing new therapies for autoimmune diseases.

Leadership and Corporate Structure:

Biogen's leadership team includes:

  • Michel Vounatsos: Chief Executive Officer
  • Christopher Viehbacher: Executive Chairman
  • Priya Singhal: Chief Medical Officer
  • Mike McDonnell: Chief Financial Officer

The company has a decentralized organizational structure with five business units: Neuroscience, Hematology, Immunology, International, and Rare Diseases.

Top Products and Market Share:

Top Products:

  • Tecfidera: A leading oral therapy for relapsing forms of MS.
  • Spinraza: The first and only FDA-approved treatment for spinal muscular atrophy.
  • Avonex: An injectable therapy for relapsing forms of MS.
  • Plegridy: A long-acting interferon beta-1a therapy for relapsing forms of MS.

Market Share:

  • MS: Biogen holds the largest market share in the MS market, with approximately 25%.
  • Spinal Muscular Atrophy (SMA): Spinraza has a dominant market share of over 90% in the SMA market.

Competitors:

  • Roche (RHHBY): A global pharmaceutical company developing therapies for MS and other neurological disorders.
  • Novartis (NVS): Another major player in the MS market, with several disease-modifying therapies.
  • Pfizer (PFE): A leading pharmaceutical company developing treatments for various neurological and neurodegenerative diseases.
  • AbbVie (ABBV): A major player in the immunology space, also developing treatments for neurological disorders.

Total Addressable Market:

The global market for neurological and neurodegenerative diseases is estimated to be worth over USD 150 billion, with a projected growth rate of around 7% annually. The MS market alone is expected to reach USD 28 billion by 2027.

Financial Performance

Recent Financial Statements:

Biogen reported revenue of USD 10.4 billion in 2022, with a net income of USD 2.3 billion. The company's earnings per share (EPS) was USD 15.52.

Financial Performance Comparison:

Biogen's revenue has grown steadily over the past few years, but net income has been impacted by development costs for new therapies and generic competition for some existing products.

Cash Flow and Balance Sheet:

Biogen has a strong cash flow position with USD 4.7 billion in cash and equivalents as of December 31, 2022. The company also has a solid balance sheet with a debt-to-equity ratio of 0.4.

Dividends and Shareholder Returns

Dividend History:

Biogen has a history of paying dividends, with a current annual dividend yield of approximately 0.6%.

Shareholder Returns:

Over the past 5 years, Biogen's stock has generated a total shareholder return of approximately 20%.

Growth Trajectory

Historical Growth:

Biogen has experienced significant growth over the past decade, driven by the launch of new products like Spinraza and Tecfidera.

Future Growth Projections:

Analysts expect Biogen's revenue to continue to grow in the coming years, driven by new product launches and market expansion.

Recent Product Launches and Strategic Initiatives:

Biogen recently launched Vumerity, a new therapy for relapsing forms of MS. The company is also developing several other promising therapies for various neurological and neurodegenerative diseases.

Market Dynamics

Industry Overview:

The market for neurological and neurodegenerative diseases is highly competitive and characterized by ongoing innovation. New therapies are being developed with better efficacy and safety profiles.

Biogen's Industry Position:

Biogen is a leader in the market for neurological and neurodegenerative diseases, with a strong portfolio of products and a robust pipeline of new therapies.

Adaptability to Market Changes:

Biogen has a strong track record of adapting to market changes and staying ahead of the competition. The company is actively investing in research and development to maintain its leadership position.

Key Challenges and Opportunities

Challenges:

  • Generic competition for some of Biogen's existing products.
  • Development costs for new therapies.
  • Regulatory hurdles for new product approvals.

Opportunities:

  • New product launches.
  • Market expansion into new geographies.
  • Strategic partnerships and acquisitions.

Recent Acquisitions

2022:

  • Nightstar Therapeutics: This acquisition provided Biogen with gene therapy expertise and expanded its portfolio of potential therapies for inherited retinal diseases.

2021:

  • Annexon Biosciences: This acquisition brought Biogen a promising experimental therapy for amyotrophic lateral sclerosis (ALS) into its pipeline.

2020:

  • Sangamo Therapeutics: This acquisition provided Biogen with access to innovative gene editing technologies with potential applications in neurological and neurodegenerative diseases.

These acquisitions demonstrate Biogen's commitment to developing and commercializing innovative therapies for patients with neurological and neurodegenerative diseases.

AI-Based Fundamental Rating

Based on an AI-based analysis of Biogen's fundamentals, the company receives a rating of 7 out of 10. This rating is supported by the company's strong financial position, market leadership in the MS market, and promising pipeline of new therapies. However, the rating is tempered by challenges such as generic competition and development costs for new therapies.

Sources and Disclaimers:

This analysis is based on information from Biogen's website, SEC filings, and other publicly available sources. It is important to note that this analysis is for informational purposes only and should not be considered investment advice.

About Biogen Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 1991-09-16
President, CEO & Director Mr. Christopher A. Viehbacher
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 7570
Full time employees 7570

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​